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1196Objective: The goal of this study was to analyze factors predictive of recurrence and disease-free survival in
patients with completely resected esophageal carcinoma.
Methods: We conducted a retrospective review of a prospective database to identify patients with completely
resected esophageal carcinoma. Medical records were reviewed. Recurrence rates, time to recurrence, and
disease-free survival were analyzed. The Kaplan–Meier method was used for time to event estimation, and mul-
tivariate Cox regression models were constructed to analyze factors thought to be significant in determining both
freedom from recurrence and disease-free survival.
Results: From 1988 to 2009, 465 of 500 patients underwent complete resection for esophageal carcinoma. Me-
dian follow-up for living patients was 49 months; 197 patients (42.4%) had recurrence, leading to 175 patients
dying of cancer and 22 patients living with recurrent disease. Multivariate regression adjusted for P stage iden-
tified the following variables as independent predictors of freedom from recurrence: performance status greater
than 0 (hazard ratio [HR], 1.84; 95 confidence interval [CI], 1.35–2.49];P<.001), poor differentiation (HR, 1.50;
CI, 1.12–2.01; P ¼ .006), induction therapy (HR, 1.65; CI, 1.21–2.25]; P ¼ .002), en bloc resection (HR, 0.61;
CI, 0.43–0.88; P ¼ .007), and advanced pathologic stages (II/III/IV) (HR, 5.46; CI, 3.05–9.78; P< .001).
Independent predictors of disease-free survival adjusted for P stage were performance status greater than
0 (HR, 1.73; CI, 1.34–2.23; P<.001), en bloc resection (HR, 0.63; CI, 0.47–0.84; P ¼ .002), induction therapy
(HR, 1.34; CI, 1.02–1.76; P ¼ .033), and advanced pathologic stages (II/III/IV) (HR, 3.16; CI, 2.15–4.65;
P<.001).
Conclusions: For patients with completely resected esophageal cancer, independent predictors of improved
freedom from recurrence and disease-free survival include good performance status, en bloc resection, and early
pathologic stage. (J Thorac Cardiovasc Surg 2011;141:1196-206)Earn CME credits at
http://cme.ctsnetjournals.org
The diagnosis of esophageal carcinoma carries a dismal
prognosis for the majority of patients, with more than 95%
of patients succumbing to their disease. Among the subset
of patients resected with curative intent (R-0 resection), the
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The Journal of Thoracic and Cardiovascular Surtomy or transhiatal esophagectomy rarely exceeds 30%.1-4
The primary reason for the poor results is that metastatic
disease develops in the majority of patients, suggesting
that the disease may already have disseminated at the time
of diagnosis. Although undoubtedly this is the case in
some patients, a careful analysis of the patterns of failure
after various local therapies delivered with curative intent
suggests inadequate locoregional control. For example, the
locoregional failure rate after definitive chemoradiation is
in the 30% to 40% range.5 Similarly, local failure rates after
surgical resection have been reported to be in the 30% to
40% range.6-9 Factors affecting postoperative recurrence
and disease-free survival (DFS) are often unclear. The goal
of this studywas to review our surgical experience in patients
with completely resected esophageal carcinoma and to deter-
mine predictors of recurrence and long-term DFS.PATIENTS AND METHODS
Patients
We conducted an institutional review board-approved retrospective
review of a prospectively maintained database to identify patients who
underwent esophagectomy for invasive carcinoma of the esophagus and
gastroesophageal junction between November 1987 and December 2009.
Patients with high-grade dysplasia were excluded. Hospital and officegery c May 2011
Abbreviations and Acronyms
CI ¼ confidence interval
CT ¼ computed tomography
DFS ¼ disease-free survival
FFR ¼ freedom from recurrence
HR ¼ hazard ratio
PET ¼ positron emission tomography
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graphics, preoperative clinical assessment, preoperative radiologic assess-
ment, associated comorbidities, and clinical stage. Records were also
reviewed for perioperative and pathologic data, including surgical ap-
proach, extent of resection, perioperativemortality (defined as death during
the same hospitalization or within 30 days after operation), morbidity,
tumor size, histology, pathologic stage, and use of induction or adjuvant
therapies. Patients were staged according to the TNM classification of
the sixth and seventh editions of American Joint Committee for Cancer
staging manuals.10,11
Preoperative Evaluation
Preoperative assessment was directed toward establishing a clinical
TNM stage and assessing the patients’ ability to tolerate the planned oper-
ation. Standard diagnostic and staging workup in this cohort included an
upper endoscopy with biopsy and computed tomography (CT) of the chest
and upper abdomen to evaluate locoregional extent of the disease and
exclude distant metastases. A subset of patients underwent endoscopic
ultrasonography and positron emission tomography (PET),whichwere rou-
tinely obtained preoperatively in the latter half of the cohort from 1999 to
2009. Generally, patients were considered for surgical resection if preoper-
ative evaluation revealed no evidence of distant visceral metastases or clear
evidence of direct tumor invasion of the airway ormajor vascular structures.
The presence of extensive nodal disease was not considered a contraindica-
tion to resection unless it clearly extended beyond the proposed fields of
dissection. Performance status of all patients was graded according to East-
ern Cooperative Oncology Group guideline.12 Finally, all patients under-
went detailed evaluation of pulmonary and cardiac function to determine
their ability to withstand the planned procedure. Generally, patients with
a forced expiratory volume in 1 second less than 1.5 L/sec despite aggres-
sive physiotherapy and optimal bronchodilator therapy were considered
ineligible for resection. Cardiac disease, if suspected, was carefully as-
sessed using noninvasive stress testing or coronary angiogram if necessary.
Induction and Adjuvant Therapies
Among all 500 patients, 193 had induction therapy, 179 of whom were
completely resected and included with the 465 patients with R-0 resection.
A total of 151 patients received platinum-based induction chemotherapy
before surgical resection as part of an ongoing institutional protocol, and
28 patients received induction chemoradiation. A total of 286 patients
underwent surgery without preoperative therapy, and 79 of those received
adjuvant therapy.
Surgical Resection
Surgical resection in this cohort of patients consisted of a standard esoph-
agectomy with or without thoracotomy or transthoracic en bloc esophagec-
tomy with 2- or 3-field lymphadenectomy. The basic technique of en bloc
esophagectomy has been described.13 En bloc esophagectomy was com-
monlycarriedout through3 incisions: a right thoracotomy followedby a lap-
arotomy and collar neck incision. The intrathoracic portion of the en bloc
technique included resection of the tumor-bearing esophagus withinThe Journal of Thoracic and Carawide envelope of periesophageal tissue including both pleural surfaces lat-
erally, a patch of pericardium anteriorly in patients with T2 to T3 tumors, all
lymphovascular tissue posterior to the esophagus including the thoracic
duct, and a mediastinal lymphadenectomy extending from the tracheal bi-
furcation to the hiatus. A ‘‘third field’’ lymphadenectomy was incorporated
in some patients by extending the nodal dissection to include the superior
mediastinal nodes and the nodes along the course of both recurrent laryngeal
nerves, and in some patients the deep cervical nodes located lateral and
posterior to the jugular veins with the latter performed through the cervical
incision. In the abdomen, an upper abdominal lymphadenectomy was
performed that included the common hepatic, celiac, left gastric, parahiatal,
lesser curvature, and retroperitoneal lymph nodes.
Standard resections in this cohort were done through a transhiatal or
transthoracic approach. Transhiatal esophagectomy was performed as de-
scribed by Orringer and colleagues1 through an upper abdominal incision
and a left neck incision. However, the parahiatal dissection and upper ab-
dominal nodal dissection were similar to that performed during the abdom-
inal phase of the en bloc operation. The paraesophageal and mediastinal
lymph nodes were removed as exposure allowed. During standard transtho-
racic resections, the esophagus was mobilized with its periesophageal no-
des without resection of its pleural envelope, pericardium, thoracic duct, or
superior mediastinal lymph nodes. The abdominal dissection was similar to
that described previously for en bloc and transhiatal esophagectomy. Gen-
erally, a standard esophagectomy was preferentially performed in patients
with clinical stage I disease and patients aged 80 years or more. En bloc
esophagectomy was performed in most medically fit patients aged less
than 80 years with clinical stage II or greater disease. Reconstruction of
the gastrointestinal tract was performed using a greater curvature gastric
tube in 96% of patients. Pathologic staging was determined according to
the TNM classification of the sixth and seventh editions of the American
Joint Committee for Cancer staging manuals.10,11
Follow-up
After hospital discharge, patients were seen at intervals of 3 months for
the first 2 years and every 6 months thereafter. Patients from distant
geographic regions were followed by contacting their local physician and
directly contacting the patient. CT scans of the chest and upper abdomen
were obtained every 6 months for 2 years and every year thereafter. Other
studies, such as endoscopy and PET scanning, were performed when recur-
rence was suspected.
Recurrence
Local recurrence was defined as any tumor recurrence within the field of
nodal dissection or at the anastomosis. Distant recurrencewas defined as any
tumor recurrence occurring in nodal basins outside the field of surgical dis-
section or in distant organs. The operating surgeon reported recurrence data
based on review of findings on CT, PET, endoscopy, or relevant biopsies.Survival Modeling and Statistical Analysis
Kaplan–Meier survival analysis of the date of surgery to the date of recur-
rence,with censoringof all other patients,was used to estimate freedomfrom
recurrence (FFR) after resection. DFS was defined as the date of surgery to
the date of recurrence or death from any cause. The log-rank test was used to
determine the significance of subgroup comparisons in regard to these sur-
vival end points.Median FFR andDFSwere computed, and 95% confidence
intervals (CIs) for median FFR/DFS and survival estimates at select time
points are presented to assess the precision of the obtained estimates.
Cox proportional hazards regression was used to estimate unadjusted
hazard ratios (HRs) for the associations of specific factors of interest and
survival outcomes of recurrence and death from any cause. Multivariate
Cox proportional hazards models for FFR and DFS were constructed for
the analysis of multiple patient characteristics, histopathologic features
of the tumor, and treatment regimens. The multivariate regression modelsdiovascular Surgery c Volume 141, Number 5 1197
TABLE 1. Demographic, surgical, and pathologic characteristics of
465 patients who underwent R-0 esophagectomy
Entire cohort En bloc Standard P
N 465 328 137
Male 370 (79.6%) 267 (81.4%) 103 (75.2%) .129
Age, y (median
value)
64 63 68 <.001
Performance status 0 243 (52.3%) 173 (52.7%) 70 (51.1%) .746
Performance status 1
or 2
222 (47.7%) 155 (47.3%) 67 (48.9%)
Clinical stage 0*/I 82 (19.5%) 33 (10.9%) 49 (41.2%) <.001
Clinical stage
II/III/IV
339 (80.5%) 269 (89.1%) 70 (58.8%)
Pathologic stage
0*/I
117 (25.2%) 71 (21.6%) 46 (33.6%) .007
Pathologic stage
II/III/IV
348 (74.8%) 257 (78.4%) 91 (66.4%)
Adenocarcinoma 341 (73.3%) 236 (72.0%) 105 (76.6%) .297
Proximal/mid/lower
third or GEJ
14/71/380 11/55/262 3/16/118 .281
Induction therapy 179 (38.5%) 159 (48.5%) 20 (14.6%) <.001
Perioperative
mortality
16 (3.4%) 11 (3.4%) 5 (3.6%) .284
GEJ,Gastroesophageal junction. *Clinical stage 0 denotes Tis disease preoperatively
and pathologic stage 0 denotes complete pathologic response after induction
therapies.
TABLE 2. Clinical and pathologic staging of the entire cohort of 465
patients according to pathologic staging per the 6th and 7th editions
of the American Joint Committee for Cancer staging manuals
Clinical stage Pathologic stage
6th ed. 6th ed. 7th ed.
Stage N % Stage N % N %
0* 7 1.5 0* 20 4.3 20 4.3
I 75 16.1 I 97 20.9
IIA 118 25.4 IA 70 15.1
IIB 31 6.7 IB 39 8.4
III 155 33.3 IIA 74 15.9 23 4.9
IVA 23 4.9 IIB 67 14.4 91 19.6
IVB 12 2.6 III 138 29.7
Missing 44 9.5 IIIA 85 18.3
IIIB 65 14.0
IIIC 72 15.5
IVA 23 4.9
IVB 46 9.9
Missing 0
*Clinical stage 0 denotes Tis disease preoperatively, and pathologic stage 0 denotes
complete pathologic response after induction therapies.
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treatment, cell type, and tumor differentiation. The models were con-
structed using clinical stage or pathologic stage due to colinearity between
the 2 variables, which precluded their inclusion in the models simulta-
neously. Stage of disease was defined as early stage (0 or I) or advanced
stage (II/III/IV). Before the final specification of each multivariate model,
potential colinearity between univariate predictors was assessed by the
Pearson (or Spearman-rank) correlation coefficient (for continuous predic-
tors) or the kappa statistic (for categoric predictors). The adjusted HRs for
recurrence (FFR) and recurrence or death (DFS) are presented along with
95% CIs for assessing the precision of the obtained HR estimates.
The 2-sample t test or Mann–Whitney U test was used, as appropriate,
for the comparison of continuous variables between groups. The chi-square
test or Fisher exact test was used, as appropriate, to compare categoric
variables between groups. All P values are 2-sided. All analyses were
performed in SPSS Version 18.0 (SPSS Inc, Chicago, Ill).
RESULTS
Patients
During the study period from November 1987 to Decem-
ber 2009, 500 consecutive patients with esophageal cancer
were surgically treated. Thirty-five patients were excluded
fromanalysis because they hadmicroscopically positivemar-
gins (n¼ 15) or gross residual disease (n¼ 20); the latter in-
cluded 7 patients with unsuspected distant metastases. The
overall R0 resection rate was thus 93%. Among the 465 pa-
tientswho had anR0 resection, 179were resected after induc-
tion therapy and 286 were treated with surgery alone. These
completely resected patients comprised the study group and
are the subject of all subsequent analyses. Demographic, clin-
ical, and pathologic characteristics of these patients are1198 The Journal of Thoracic and Cardiovascular Surshown in Table 1. Median age was 64 years (range, 24–89
years), and the majority of patients (79.6%) were men.
Surgical Approach and Extent of Resection
A total of 328 patients (71%) had an en bloc resection
(2-field in 129, 3-field in 199). The remaining 137 patients
(29%) had a standard resection (88 transhiatal, 49 transtho-
racic). Compared with patients treated with standard
esophagectomy, those treated by an en bloc resection
were significantly younger, had more advanced clinical
and pathologic stages, and were more likely to have
received preoperative therapy (Table 1).
Hospital Morbidity and Mortality
There were 16 deaths (3.4%) that occurred within 30
days from operation or during the same hospitalization. A
total of 281 patients (56%) had an uncomplicated postoper-
ative course. The most frequent morbidity was pulmonary
(26% of patients), followed by cardiac arrhythmia (22%
patients). Recurrent nerve injury occurred in 7% of pa-
tients. Anastomotic leaks occurred in 11.5% of patients.
Although slightly more patients had cardiopulmonary mor-
bidity after en bloc resection, only the incidence of atrial ar-
rhythmias was significantly higher after en bloc resection
(P ¼ .01). There was also no difference between the 2 ap-
proaches in the frequency of chylothoraces, infectious
complications, or recurrent nerve injuries. We have previ-
ously reported on the morbidity associated with en bloc
resections.13,14
Induction Therapy
Of the 179 patients treated preoperatively, 151 had re-
ceived platinum-based chemotherapy and 28 were treatedgery c May 2011
TABLE 3. Crude recurrence rates after en bloc and standard resection in patients treated with surgery alone (n ¼ 286)
Pathologic stage 6th ed. Any recurrence Local recurrence
I Overall
n ¼ 84
En bloc
n ¼ 42
Standard
n ¼ 42
Overall
n ¼ 84
En bloc
n ¼ 42
Standard
n ¼ 42
6 (7.1%) 3 (7.1%) 3 (7.1%) P ¼ 1.00 1 (1.2%) 1 (2.4%) 0 P ¼ 1.00
II/III/IV Overall
n ¼ 202
En bloc
n ¼ 127
Standard
n ¼ 75
Overall
n ¼ 202
En bloc
n ¼ 127
Standard
n ¼ 75
102 (50.5%) 63 (49.6%) 39 (52.0%) P ¼ .742 27 (13.4%) 17 (13.4%) 10 (13.3%) P ¼ .992
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cohort included 51.5% (163/319) who received preopera-
tive therapy from 1999 to 2009, compared with 11.0%
(16/146) in the earlier half of the cohort treated from
1987 to 1998 (P<.001).
Pathologic Findings
Clinical and pathologic staging of the entire cohort is
detailed in Table 2, which was determined according to
the sixth and seventh editions of American Joint Committee
for Cancer staging manuals.10,11 At the time of surgical
resection, slightly less than half of the patients (44.5%)
had pathologic stage III and IV disease. The most
common tumor cell type was adenocarcinoma (73.3%),
and most tumors were located in the lower third of the
esophagus (Table 1). The median number of lymph nodes
removed among all patients was 26. The number of har-
vested lymph nodes was significantly higher for the en
bloc group compared with the standard group (median 31
vs 17, P<.001). A total of 265 patients (57%) had patho-
logically involved lymph nodes. The median number of
positive lymph nodes was 3 regardless of the extent of dis-
section. After induction therapy, 20 patients (10%) had
a complete pathologic response.
Predictors of Freedom From Recurrence
Median follow-up for all surviving patients was 49
months. Of the 465 patients who had an R-0 resection,
tumor recurrence developed in 197 (42.4%). Among 286
patients treated by surgery without induction therapy, local
failure as previously defined was 10.7% after en bloc resec-
tion and 8.5% after standard resection, for an overall local
recurrence rate of 9.8%. Table 3 illustrates stage matched
comparisons of overall and local recurrence rates for early
and advanced disease, which demonstrate no difference
between the 2 resection techniques. These results were un-
changed when the crude recurrence rates were calculated
for the entire cohort of 465 patients who had an R-0 resec-
tion (data not shown).
For patients with early pathologic stage disease, there
was no difference between the en bloc and standard tech-
niques in FFR for the entire cohort (Figure 1) and for those
patients treated by surgery alone (Figure 2). In patients with
locally advanced stage disease treated by surgery alone, en
bloc resection (compared with standard resection) was asso-The Journal of Thoracic and Carciated with a significant improvement in FFR (Figure 2); the
median FFR after en bloc and standard resections was 32.4
months (95% CI, 10.3–54.5) and 20.7 months (95% CI,
11.7–29.8), respectively (HR, 0.64; CI, 0.43–0.96;
P ¼ .028). However, when all patients with advanced path-
ologic stage disease were analyzed, including patients
treated with induction therapy (Figure 1), there was a non-
significant trend in favor of en bloc resection with a median
time for FFR of 25.0 months (95% CI, 16.8–33.2) versus
20.7 months (95% CI, 13.2–28.3) after standard resection
(HR, 0.82; CI, 0.58–1.14; P ¼ .237). Results were the
same when analysis of FFR was repeated using the AJCC
Cancer Staging Manual, 7th ed.11
To further elucidate independent predictors of FFR,
multivariate regression analysis was also performed with
variables thought to be associated with FFR. The model
demonstrated that performance status, tumor differentia-
tion, extent of resection, and use of induction therapy
were significant independent predictors of FFR, in addition
to pathologic stage (Table 4). Results were similar when the
model was adjusted for clinical stage, with the exception of
induction therapy, which was no longer a significant predic-
tor of FFR in this model (Table 5).
Predictors of Disease-Free Survival
For the 465 patients in whom an R-0 resection was per-
formed, 5-year DFS was 39.8% (95% CI, 34.9–44.7) and
10-year DFS was 31.8% (95% CI, 26.5–37.1). For patients
with clinical stage 0/I disease,10 there was no significant dif-
ference in DFS between the en bloc group and the standard
resection group (Figure 3). However, for patients with clin-
ical stage II or greater disease, DFS was significantly pro-
longed after en bloc esophagectomy. Median DFS was
23.6 months (95% CI, 17.8–29.4) after en bloc resection
and 12.2 months (95% CI, 5.2–19.2) after standard resec-
tion (HR, 0.70; CI, 0.50–0.97; P ¼ .033).
For patients with pathologic stage 0/I disease,10 there was
again no significant difference in DFS between the en bloc
group and the standard resection group (5 year-DFS
75.7% [95% CI, 62.2–90.4] vs 76.3% [95% CI, 65.3–
86.1]; Figure 4). However, for patients with pathologic stage
II/III/IV disease, DFS was significantly improved after en
bloc resection compared with standard resection (HR,
0.66; CI, 0.50–0.88; P ¼ .004). Median DFS was 19.0
months (95% CI, 14.0–24.0) after en bloc and 12.2 monthsdiovascular Surgery c Volume 141, Number 5 1199
FIGURE 1. FFR for the whole cohort, stratified as early (stage 0/I) or advanced (stage II/III/IV) pathologic stage.
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were restaged by criteria of the AJCC Cancer Staging Man-
ual, 7th ed,11 similar results were observed (data not shown).
Multivariate analysis of DFS revealed that the extent of
resection, performance status, and use of induction therapy
were significant independent predictors of DFS (Table 6).
However, because a significant interaction between patho-
logic stage and extent of resection was observed (interac-
tion coefficient P ¼ .054), the multivariate model was
stratified by early or advanced pathologic stage. Because
of the relatively small numbers and infrequency of events
in the early-stage subgroup, there was instability in the
model estimates and the data are not shown (ie, the multi-
variate model as originally specified for DFS could not be
supported in the early-stage subgroup). Analysis of the ad-
vanced stage subgroup is shown in Table 7. The extent of
resection and performance status emerged as significant in-
dependent factors, as they had when the entire cohort was
analyzed, whereas the association between induction
therapy and worse DFS was not significant.
When the model was adjusted for clinical stage instead of
pathologic stage, performance status, extent of resection,
and tumor differentiation emerged as significant indepen-
dent predictors of DFS, whereas induction therapy was no
longer a significant predictor (Table 8). When the interac-
tion between extent of resection and clinical stage was1200 The Journal of Thoracic and Cardiovascular Surtested in this model, therewas no evidence of interaction be-
tween these 2 variables (interaction coefficient P ¼ .911).
DISCUSSION
In contrast with resectional surgery for malignant
disease in organs such as the lung, colon, and breast,
esophagectomy for esophageal carcinoma remains a non-
standardized operation in almost every respect other than
its basic concept. Surgeons around the world performing
the operation are properly influenced by prior training, per-
sonal experience, and often strongly held beliefs about the
‘‘biology’’ of this neoplasm. In the absence of standardiza-
tion of the technique of resection, particularly as it relates to
the extent of nodal dissection, it is not possible to rationally
compare outcomes from various centers, let alone evaluate
the impact of various induction therapy protocols. In the
current work, our aim was to examine the factors influenc-
ing disease recurrence and DFS in a cohort of patients
treated by surgical techniques that have been well standard-
ized and uniformly applied in a single institution over the
past 2 decades. Our results show that, for both FFR and
DFS, outcome is often dictated by multiple factors that in-
clude patient-related variables, tumor-related factors, and
treatment-related factors, including the technique of surgi-
cal resection. The results pertaining to disease recurrence
are of particular interest because we and other advocatesgery c May 2011
FIGURE 2. FFR for patients treated with surgery alone, stratified as early (stage I) or advanced (stage II/III/IV) pathologic stage.
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which en bloc resection improves survival may be through
delivery of superior local disease control.13,15,16 Previously
reported locoregional failure rates after en
bloc esophagectomy compared favorably with historical
local failure rates after transthoracic or transhiatal
esophagectomy, which have been variably reported to be
in the 30% to 40% range.6-9 Although the use of
induction chemoradiation may have provided better local
control, local recurrence rates after transhiatal resection
remained high at approximately 20%.7 Notably, the current
analyses show no significant difference in locoregionalTABLE 4. Multivariate Cox regression, freedom from recurrence
adjusted for pathologic stage
HR P
Age 0.99 (0.97–1.00) .073
Male gender 1.28 (0.87–1.90) .211
Performance status>0 1.84 (1.35–2.49) <.001
Poor differentiation 1.50 (1.12–2.01) .006
Squamous cell type 1.03 (0.74–1.44) .845
Induction 1.65 (1.21–2.25) .002
En bloc resection 0.61 (0.43–0.88) .007
Advanced pathologic stage 5.46 (3.05–9.78) <.001
HR, Hazard ratio.
The Journal of Thoracic and Carcrude recurrence rates between patients treated with or
without en bloc resection. The local recurrence rates
reported in this article are essentially similar to those re-
ported by Hulscher and colleagues17 in a randomized trial
comparing transhiatal resection with transthoracic en bloc
esophagectomy. These results, though interesting, should
be interpreted within the context of 2 important consider-
ations. First, approximately 40% of patients treated by stan-
dard resections had clinical stage 0/I disease compared with
only 10% of patients in the en bloc group, a highly signif-
icant difference. Conversely, approximately 80% of the en
bloc group had pathologically staged locally advancedTABLE 5. Multivariate Cox regression, freedom from recurrence
adjusted for clinical stage
HR P
Age 0.99 (0.97–1.00) .157
Male gender 1.29 (0.85–1.95) .233
Performance status>0 2.02 (1.47–2.77) <.001
Poor differentiation 1.74 (1.28–2.38) <.001
Squamous cell type 0.84 (0.59–1.20) .332
Induction 1.35 (0.98–1.87) .067
En bloc resection 0.60 (0.40–0.90) .014
Advanced clinical stage 6.46 (2.90–14.38) <.001
HR, Hazard ratio.
diovascular Surgery c Volume 141, Number 5 1201
FIGURE 3. DFS for the entire cohort, stratified as early (stage 0/I) or advanced (stage II/III/IV) clinical stage.
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mately half the patients. Second, during the conduct of
the transhiatal resection we have essentially performed an
upper abdominal node dissection that is identical to that car-
ried out during the abdominal phase of the en bloc opera-
tion. The median number of lymph nodes resected in the
standard resection group was 17, a number that compares
favorably with published recommendations for adequate
nodal staging, and therefore may have contributed to
some extent in decreasing local failure in the upper
abdomen.18
Despite the similarity in the crude rates of local recur-
rence, it seems there is a significant difference in the FFR
between the 2 procedures. Patients with advanced patho-
logic stage who were treated by surgery alone had a signif-
icant 36% reduction in the hazard for recurrence after en
bloc resection and an increase in the FFR by approximately
1 year. Although there was a similar trend favoring en bloc
resection when all patients with advanced pathologic stages
were analyzed (including patients treated by neoadjuvant
therapy), statistical significance was lost probably because
the magnitude of the beneficial effect was reduced by the in-
clusion of a group of patients with biologically more viru-
lent disease all treated by en bloc resection. This is1202 The Journal of Thoracic and Cardiovascular Surconsistent with the pathologic stage-adjusted multivariable
model of the entire cohort, which showed that en bloc
resection reduced the hazard for recurrence, whereas induc-
tion therapy was significantly associated with recurrent
disease. It is obviously of equal interest that the FFR did
not differ significantly between the 2 resection techniques
in patients with early-stage disease (cT1N0/pT1N0) or
those downstaged to ypT0-1/N0 after preoperative therapy.
This report also analyzed the factors that may be associ-
ated with prolonged DFS. Only performance status, extent
of resection, and stage consistently emerged from the Cox
regressionmodels as independent predictors of DFS. To fur-
ther define the role of surgical resection, we examined DFS
after the 2 types of resection in various clinical and patho-
logic stage groupings. Our results suggest that patients
with early-stage disease (cT1N0/pT1N0) can be appropri-
ately and sufficiently treated by an en bloc or a standard re-
section. Conversely, the data also suggest that an en bloc
resection results in a significant improvement in DFS com-
pared with standard resection in patients with advanced
clinical or pathologically staged disease. In the absence of
a demonstrable effect on local failure rates, the therapeutic
benefit of en bloc resection may be derived from a wider
lymphadenectomy with excision of both clinically apparentgery c May 2011
FIGURE 4. DFS for the entire cohort, stratified as early (stage 0/I) or advanced (stage II/III/IV) pathologic stage (AJCC Cancer Staging Atlas, 6th ed10).
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the total number of resected nodes is a significant determi-
nant of survival in node-positive patients treated by surgery
alone.19 In comparison with patients with 16 or fewer lymph
nodes resected, the HR for death was significantly reduced to
0.51 when 17 to 25 nodes were resected and 0.39 when 26 to
40 nodes were removed. Recent reviews of the Surveillance,
Epidemiology, and End-Results database and of an interna-
tional database reported increased survival with higher total
negative lymph node counts and higher total lymph node
counts.20,21 Thus, extended lymphadenectomy, beyond its
influence on stage migration, may have a therapeuticTABLE 6. Multivariate Cox regression, disease-free survival adjusted
for pathologic stage
HR P
Age 1.00 (0.99–1.01) .575
Male gender 1.16 (0.85–1.58) .360
Performance status>0 1.73 (1.34–2.23) <.001
Poor differentiation 1.25 (0.98–1.60) .069
Squamous cell type 1.25 (0.94–1.67) .120
Induction 1.34 (1.02–1.76) .033
En bloc resection 0.63 (0.47–0.84) .002
Advanced pathologic stage 3.16 (2.15–4.65) <.001
HR, Hazard ratio.
The Journal of Thoracic and Carbenefit by removing lymph nodes containing occult
metastatic nodal disease. Extended lymphadenectomy may
be important even after induction therapy, because in the
majority of patients neither preoperative chemotherapy nor
preoperative chemoradiation reliably eliminates nodal
disease.22 The controversy around the extent of lymph node
dissection for cancer has occupied esophageal surgeons for
decades, and the results of a recent randomized trial has
done little to quell the controversy.17 In that trial, 220 patients
were randomly assigned to en bloc or transhiatal esophagec-
tomy. Although the results tantalizingly showed a 34% rela-
tive improvement in both overall and DFS after en blocTABLE 7. Multivariate Cox regression, disease-free survival in
patients with advanced pathologic stages
HR P
Age 1.00 (0.99–1.01) .653
Male gender 1.17 (0.83–1.63) .365
Performance status>0 1.80 (1.36–2.37) <.001
Poor differentiation 1.26 (0.98–1.63) .077
Squamous cell type 1.29 (0.96–1.75) .094
Induction 1.28 (0.96–1.70) .091
En bloc resection 0.56 (0.41–0.76) <.001
HR, Hazard ratio.
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TABLE 8. Multivariate Cox regression, disease-free survival adjusted
for clinical stage
HR P
Age 1.00 (0.99–1.02) .761
Male gender 1.14 (0.81–1.60) .465
Performance status>0 1.95 (1.49–2.57) <.001
Poor differentiation 1.42 (1.09–1.86) .009
Squamous cell type 1.06 (0.78–1.46) .693
Induction 1.22 (0.91–1.62) .178
En bloc resection 0.62 (0.45–0.87) .006
Advanced clinical stage 2.75 (1.71–4.41) <.001
HR, Hazard ratio.
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Sesophagectomy (39% en bloc vs 29% transhiatal), statistical
significancewas not achieved. The authors subsequently pub-
lisheda subgroupanalysis and showed that the long-termben-
efit of an en bloc resection could be attributed to the subgroup
of patients with lower third carcinoma of the esophagus, in
whom the estimated 5-year survival benefit of an en bloc re-
section was 14%.23 The authors also showed that for patients
with limited nodal disease (1–8 positive lymph nodes) DFS
was significantly improved after en bloc resection.24 In the
absence of anothermore definitive randomized trial, this con-
troversy is likely to continue.
Limitations
Despite our best efforts to collect the data prospectively,
this study remains a retrospective review and thus subject to
all the inherent limitations of such reviews. For example,
unintended biases such as selection or referral bias cannot
be reasonably excluded. This study also extended over
a 22-year period, during which there has been evolution in
staging techniques and multimodality treatment of esopha-
geal cancer. More recently, there has been an obvious shift
toward increasing use of PET scanning in preoperative stag-
ing and of preoperative chemotherapy or chemoradiation.
CONCLUSIONS
Our results suggest that, for patients with good perfor-
mance status and clinically staged as stage II or greater,
en bloc resection is associated with a higher probability of
FFR and a significant improvement in DFS. Patients with
clinical stage I may be adequately treated by a standard re-
section technique.
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Dr David Rice (Houston, Tex). I have nothing to disclose.
Congratulations on an excellent presentation, Paul, and thank
you very much for giving me the slides and the manuscript well
in advance of the meeting.
Dr Lee and his colleagues from Cornell present an impressive
series of 500 patients who underwent an esophagectomy forgery c May 2011
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Sesophageal cancer over a 22-year period. The majority of patients
underwent surgery alone, but a third also received induction che-
motherapy. Two thirds had an en bloc esophagectomy with either
a 2-field or 3-field lymphadenectomy. Of the remaining one third,
the majority of these had a transhiatal resection. Consistent with
most other large Western series, adenocarcinoma predominated
and over 80% of cases were clinical stage II or higher. I applaud
the authors on such a low mortality rate.
There is much controversy regarding the oncologic adequacy of
transhiatal esophagectomy. Proponents argue that no randomized
trial has shown significant inferiority in terms of survival, and cer-
tainly pulmonary morbidity is lessened. What is beyond doubt,
however, is that transhiatal esophagectomy compromises on the
extent of mediastinal node dissection that is achievable. Whether
or not this influences local recurrence and survival is the subject
of this manuscript. In multivariate analysis, Lee and colleagues
found that en bloc esophagectomy was an independent predictor
of longer disease-free survival. The survival benefit of en bloc
esophagectomy compared with the standard approach was espe-
cially marked for patients with stage III and stage IV tumors. Nev-
ertheless, there was only a marginal difference in the proportion of
isolated local recurrences that favored the en bloc approach by
only 3 percentage points.
My first question to Dr Lee and his colleagues is whether factors
other than a less extensive nodal dissection could have resulted in
the worse disease-free survival seen with a standard esophagec-
tomy. Is it possible that patients who did not undergo en bloc
esophagectomy had factors that would have predicted poor out-
come anyway and that we may be dealing with selection bias? Fur-
thermore, was there any difference in cancer-specific death
between the standard and the en bloc groups?
DrLee.Thank you, Dr Rice, for those very thoughtful questions
and your comments.
To answer your question, we did look at the performance status
between the en bloc group and the non–en bloc group and there
was no difference in terms of performance status. Each group
was pretty much evenly split with PS0 and PS1. It is true that
the en bloc group had younger patients. The median age was 63
as opposed to 68. And when we did look at comorbidities, there
seemed to be a high incidence of severe pulmonary artery disease
in the transhiatal group. Nonetheless, we did look at the cancer-
specific survival and we excluded those patients who died from
other causes in the analysis. We found that for stage I there was
no difference; however, for stage II, III, and IV, there was a signif-
icant difference in improved cancer-specific survival in the en bloc
group in contrast to the non–en bloc group.
Dr Rice.My second question pertains to the extent of lympha-
denectomy required. As you know, the trial by Hulscher and col-
leagues, which is a randomized trial comparing en bloc
esophagectomy to transhiatal esophagectomy, although there
was no significant survival difference shown overall, when you
broke down patients into whether or not they were N0 versus pa-
tients who had 1 to 8 positive nodes and patients who had greater
than 8 positive nodes, there actually was a statistically significant
improvement in survival favoring the en bloc group for the group
of patients who had 1 to 8 positive nodes. In your analysis, were
you able to find any subpopulations of patients who seemed to de-
rive the most benefit from the enbloc approach and, if so, are thereThe Journal of Thoracic and Carany preoperative indicators that predict which patients might ben-
efit from a more extensive node dissection?
Dr Lee. Dr Altorki had published in 2001 in the Annals of Sur-
gery that looked at the number of positive lymph nodes and the pa-
tients who hadmore than 7 positive lymph nodes, again, under pN3
in the new staging system, those patients who had undergone en
bloc esophagectomy did a lot worse. So it seems if the patient
has anywhere from 1 to 6 positive lymph nodes, that patient prob-
ably gleans the most benefit from en bloc resection. But, as you
know, it is very difficult, even with endoscopic ultrasound and
PET scan, to tell precisely how many lymph nodes are involved,
andwe strugglewith the clinical staging under the new staging sys-
tem with that question.
Dr Rice. Lastly, I was struck by how few patients underwent
preoperative chemoradiation. Any potential benefit of induction
chemotherapy is likely due to the eradication of systemic micro-
metastases. Perhaps in the setting of en bloc esophagectomy, the
value of preoperative radiation would be negated. However, induc-
tion chemoradiation is, rightly or wrongly, a widely accepted treat-
ment regimen in North America. How do you think your results
should be interpreted by surgeons who are advocates of preopera-
tive chemoradiation?
Thank you very much.
Dr Lee. In our study, 80% of patients who had a recurrence ac-
tually recurred distantly. So it’s hard to imagine, given an en bloc
resection, to give another local therapy 4 or 5 weeks before an en
bloc esophagectomy. You are mainly just targeting less than 10%
of the patients. For the remaining 90% of the patients, you are
compromising probably the only treatment, which is chemother-
apy, to address the systemic disease issues.
Dr Rice. Thank you very much. I greatly enjoyed the presenta-
tion. Congratulations.
Dr Scott Swanson (Boston, Mass). I was interested in your lo-
cal recurrence rate. If I added it up correctly, it was 9 plus 4, or
about 13%, and in our published series in 2001 from the Brigham,
we had about a 3% local recurrence. Can you tell us a little more
about where it occurred and why you think it did?Was it less com-
mon in the en bloc patients?
Dr Lee. We define local recurrence as any recurrence within
a field dissection. So, for the patientwho has a 3-field lymphadenec-
tomy and recurs in the neck, we count that as a local recurrence. I
agree that the isolated local recurrence is 9%, and when you put
the two together, the recurrence rate is 13%, but bear in mind that
I think that the patients we are doing en bloc on are patients who
have locally advanced disease and, comparing it to conventional se-
ries, the recurrence rate is reported anywhere from30% to as high as
60% in traditional surgical series. I applaud your results in achiev-
ing a very low local recurrence rate but I think the 13% is pretty low
when we compare it with the conventional esophagectomies.
Dr Antoon Lerut (Leuven, Belgium). Thank you. These are ex-
cellent results indeed.
I would just like to indicate that there is our own experience and
also from The Netherlands that, in fact, there is a direct correlation
between complications and recurrences. I assume that the patients
who have a lesser performance status are thosewho are more likely
to have complications. So I assume that it is not so much the per-
formance status but rather the complications—linked, of course, to
a lesser performance status—that are in fact the reason for thediovascular Surgery c Volume 141, Number 5 1205
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Shigher recurrence rate. Have you checked that particular issue?
And related to that question is what do you do with the patient
with a lesser performance status who is presenting with a stage
III carcinoma? Are you going to operate?
Dr Lee.When we look at our overall mortality, there is no dif-
ference between the en bloc and the non–en bloc group. It is be-
tween 3% and 4%. We have not looked at the postoperative
complications in this study but we do recognize in other series
that the en bloc group has a longer ICU stay, a higher incidence
of recurrent nerve injury, and more postoperative morbidity. But
we will be able to get our mortality down as low as 3% with our
en bloc group. In terms of postoperative complications, this study
has not addressed that.
DrMarkKrasna (Towson,Md).Excellent survival results. I have
2 quick questions. The first relates to the group that had transhiatal
esophagectomy. Can you tell us, on average, because you had
a very good listing of the lymph nodes resected, howmany lymph no-
des were you able to resect in the transhiatal esophagectomy group?
Dr Lee. When comparing the en bloc versus the non–en bloc,
the average is 34 in the en bloc and roughly 17 in the transhiatal
group. So we were able to average about 17 lymph nodes.
Dr Krasna. Seventeen for the transhiatal?
Dr Lee. In the transhiatal group. The abdominal dissection
is identical. The only difference, obviously, is the mediastinal
dissection.1206 The Journal of Thoracic and Cardiovascular SurDr Krasna. And the other question, again, to drill down to
something Dr Rice was alluding to, is the use of either neoadju-
vant or adjuvant therapy. Because the majority of your failures
were distant, I would agree that you definitely want to give these
patients chemotherapy. The question would be are you now go-
ing to change your regimen and offer all your patients neoadju-
vant chemotherapy or are you going to be offering all of your
patients adjuvant therapy and, if so, which approach would you
choose?
Dr Lee. It is our standard to offer any patients who are stage II
or greater disease induction chemotherapy. As we all know, they
can tolerate chemotherapy better in the preoperative setting rather
than in the postoperative setting.
Dr Raphael Bueno (Boston, Mass). The en bloc technique that
you are using, is it still the one in which you take the thoracic duct,
sometimes the azygos, and how is that going to be different from
the thoracotomy resection? You had a transhiatal and a thoracot-
omy cohort. How is the thoracotomy cohort different technically
from the en bloc technique?
Dr Lee.With a transthoracic non–en bloc, you leave the tho-
racic duct and then you just take the esophagus. You do not go
into the ipsilateral pleura and you do not do a third-field lymph
node dissection. So it is the McKeown, and sometimes patients
did have the Ivor Lewis, which is a standard non–en bloc
resection.gery c May 2011
